Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of DWJ1451 in Patients With Hypertension and Dyslipidemia
NCT04161001Phase 3Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Nov 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of amlodipine + olmesartan + ezetimibe + rosuvastatin in hypertension (HTN), dyslipidemia, sponsored by Daewoong Pharmaceutical. Status: unknown.
02
Drugs
amlodipine + olmesartan + ezetimibe + rosuvastatin
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT04161001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04161001.